myriad_S_stacked.png
Myriad Genetics to Participate in Stephens Annual Investment Conference
November 09, 2023 07:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in the...
myriad_S_stacked.png
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
November 08, 2023 21:20 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced the...
myriad_S_stacked.png
Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
November 08, 2023 16:10 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced that...
myriad_S_stacked.png
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
November 06, 2023 16:05 ET | Myriad Genetics, Inc.
Highlights: Third quarter testing volume grew 18% year-over-year, excluding contributions from the SneakPeek® Early Gender DNA Test, the fifth consecutive quarter of double-digit year-over-year...
Sam Raha
Myriad Genetics Appoints Sam Raha as Chief Operating Officer
November 01, 2023 09:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief...
myriad_S_stacked.png
Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
October 31, 2023 16:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on...
myriad_S_stacked.png
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
October 26, 2023 08:00 ET | Myriad Genetics, Inc.
Partnership covers development of lab-developed and distributable kit-based companion diagnostic testsCombined strengths in assay development, clinical testing, and regulatory approvals offers pharma...
myriad_S_stacked.png
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
September 28, 2023 07:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey...
myriad_S_stacked.png
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
September 19, 2023 09:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic...
myriad_S_stacked.png
Myriad Genetics Issues 2022 Environmental, Social and Governance Report
September 19, 2023 07:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social...